NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
SN BioScience
Cue Biopharma
National Institutes of Health Clinical Center (CC)
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
AstraZeneca
Sichuan Enray Pharmaceutical Sciences Company
Alaunos Therapeutics
Novita Pharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc
Exelixis
Laval University
Labcorp Corporation of America Holdings, Inc
Stanford University
Purple Biotech Ltd.
Cyteir Therapeutics, Inc.
Acepodia Biotech, Inc.
Eli Lilly and Company
Astellas Pharma Inc
Pfizer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Stanford University
DxTerity Diagnostics
Xencor, Inc.
Cedars-Sinai Medical Center
University Medical Center Groningen
Exelixis
Eli Lilly and Company
Celldex Therapeutics
ZielBio, Inc.
Dana-Farber Cancer Institute
Pfizer
Corvus Pharmaceuticals, Inc.
The Canadian College of Naturopathic Medicine
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
Emory University
Klus Pharma Inc.
Biologics & Biosimilars Collective Intelligence Consortium
Revolution Medicines, Inc.
Fate Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Corcept Therapeutics
Istituto Clinico Humanitas